Chinese government considers mixing COVID-19 vaccines for boost amid low efficacy
China’s top disease control official says the government is considering mixing COVID-19 vaccines to give them a boost as their effectiveness showed to be low.
Read the latest updates in our dedicated coronavirus section.
Chinese vaccines “don’t have very high protection rates,” said the director of the China Centers for Disease Control, Gao Fu, at a conference Saturday in the southwestern city of Chengdu.
“It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunization process,” Gao said.
Experts say mixing vaccines, or sequential immunization, might boost effectiveness rates. Trials around the world are looking at mixing of vaccines or giving a booster shot after a longer time period. Researchers in Britain are studying a possible combination of Pfizer and AstraZeneca vaccines.
Gao gave no details of possible changes in strategy but mentioned mRNA, a previously experimental technique used by Western vaccine developers while China’s drug makers used traditional technology.
“Everyone should consider the benefits mRNA vaccines can bring for humanity,” Gao said. “We must follow it carefully and not ignore it just because we already have several types of vaccines already.”
Gao previously raised questions about the safety of mRNA vaccines. He was quoted by the official Xinhua News Agency as saying in December he couldn’t rule out negative side effects because they were being used for the first time on healthy people.
Chinese state media and popular health and science blogs also have questioned the safety and effectiveness of the Pfizer vaccine, which uses mRNA.
As of April 2, some 34 million people have received both of the two doses required by Chinese vaccines and about 65 million received one, according to Gao.
With the Associated Press
Johnson & Johnson’s COVID-19 vaccine under EU review over blood clots
AstraZeneca vaccine and blood clots: Here’s what you need to know
South African variant can ‘break through’ Pfizer COVID-19 vaccine: Israeli study